167 related articles for article (PubMed ID: 28013121)
1. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for
Pozzi OR; Zalutsky MR
Nucl Med Biol; 2017 Mar; 46():43-49. PubMed ID: 28013121
[TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.
Pozzi OR; Zalutsky MR
J Nucl Med; 2007 Jul; 48(7):1190-6. PubMed ID: 17574991
[TBL] [Abstract][Full Text] [Related]
3. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.
Pozzi OR; Zalutsky MR
J Nucl Med; 2005 Aug; 46(8):1393-400. PubMed ID: 16085599
[TBL] [Abstract][Full Text] [Related]
4. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles.
Pozzi OR; Zalutsky MR
J Nucl Med; 2005 Apr; 46(4):700-6. PubMed ID: 15809494
[TBL] [Abstract][Full Text] [Related]
5. Labeling Monoclonal Antibody with α-emitting
Vaidyanathan G; Pozzi OR; Choi J; Zhao XG; Murphy S; Zalutsky MR
Cancer Biother Radiopharm; 2020 Sep; 35(7):511-519. PubMed ID: 32109139
[No Abstract] [Full Text] [Related]
6. Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure.
Lindegren S; Albertsson P; Bäck T; Jensen H; Palm S; Aneheim E
Cancer Biother Radiopharm; 2020 Aug; 35(6):425-436. PubMed ID: 32077749
[TBL] [Abstract][Full Text] [Related]
7. Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials.
Aneheim E; Albertsson P; Bäck T; Jensen H; Palm S; Lindegren S
Sci Rep; 2015 Jul; 5():12025. PubMed ID: 26169786
[TBL] [Abstract][Full Text] [Related]
8. Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates.
Teze D; Sergentu DC; Kalichuk V; Barbet J; Deniaud D; Galland N; Maurice R; Montavon G
Sci Rep; 2017 May; 7(1):2579. PubMed ID: 28566709
[No Abstract] [Full Text] [Related]
9. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
Kozempel J; Mokhodoeva O; Vlk M
Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
[TBL] [Abstract][Full Text] [Related]
10. Development of a preclinical
Crawford JR; Yang H; Kunz P; Wilbur DS; Schaffer P; Ruth TJ
Nucl Med Biol; 2017 May; 48():31-35. PubMed ID: 28193502
[TBL] [Abstract][Full Text] [Related]
11. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
Zalutsky MR; Vaidyanathan G
Curr Pharm Des; 2000 Sep; 6(14):1433-55. PubMed ID: 10903402
[TBL] [Abstract][Full Text] [Related]
12. Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins.
Talanov VS; Yordanov AT; Garmestani K; Milenic DE; Arora HC; Plascjak PS; Eckelman WC; Waldmann TA; Brechbiel MW
Nucl Med Biol; 2004 Nov; 31(8):1061-71. PubMed ID: 15607488
[TBL] [Abstract][Full Text] [Related]
13. Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.
Guérard F; Gestin JF; Brechbiel MW
Cancer Biother Radiopharm; 2013 Feb; 28(1):1-20. PubMed ID: 23075373
[TBL] [Abstract][Full Text] [Related]
14. Astatine-211 imaging by a Compton camera for targeted radiotherapy.
Nagao Y; Yamaguchi M; Watanabe S; Ishioka NS; Kawachi N; Watabe H
Appl Radiat Isot; 2018 Sep; 139():238-243. PubMed ID: 29864741
[TBL] [Abstract][Full Text] [Related]
15. Assessing the 210At impurity in the production of 211At for radiotherapy by 210Po analysis via isotope dilution alpha spectrometry.
Schultz MK; Hammond M; Cessna JT; Plascjak P; Norman B; Szajek L; Garmestani K; Zimmerman BE; Unterweger M
Appl Radiat Isot; 2006; 64(10-11):1365-9. PubMed ID: 16563782
[TBL] [Abstract][Full Text] [Related]
16. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
Zalutsky MR; Zhao XG; Alston KL; Bigner D
J Nucl Med; 2001 Oct; 42(10):1508-15. PubMed ID: 11585865
[TBL] [Abstract][Full Text] [Related]
17. Production, isolation, and shipment of clinically relevant quantities of astatine-211: A simple and efficient approach to increasing supply.
McIntosh LA; Burns JD; Tereshatov EE; Muzzioli R; Hagel K; Jinadu NA; McCann LA; Picayo GA; Pisaneschi F; Piwnica-Worms D; Schultz SJ; Tabacaru GC; Abbott A; Green B; Hankins T; Hannaman A; Harvey B; Lofton K; Rider R; Sorensen M; Tabacaru A; Tobin Z; Yennello SJ
Nucl Med Biol; 2023; 126-127():108387. PubMed ID: 37837782
[TBL] [Abstract][Full Text] [Related]
18. Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.
Vaidyanathan G; Zalutsky MR
Curr Radiopharm; 2011 Oct; 4(4):283-94. PubMed ID: 22202151
[TBL] [Abstract][Full Text] [Related]
19. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
[TBL] [Abstract][Full Text] [Related]
20. Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides.
Wilbur DS
Curr Radiopharm; 2011 Jul; 4(3):214-47. PubMed ID: 22201710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
